MTM(SH:688029) Sou Hu Cai Jing·2026-02-27 10:57Financial Performance - The company achieved total operating revenue of 3.191 billion yuan, an increase of 15.81% compared to the same period last year [1] - The net profit attributable to the parent company was 570 million yuan, reflecting a growth of 3.05% year-on-year [1] - The net profit attributable to the parent company after deducting non-recurring gains and losses was 557 million yuan, up by 2.40% year-on-year [1] Asset and Equity Growth - At the end of the reporting period, the company's total assets amounted to 5.434 billion yuan, representing a growth of 13.69% from the beginning of the reporting period [2] - The equity attributable to the parent company was 4.109 billion yuan, which is a 7.38% increase from the beginning of the reporting period [2] Revenue Growth Drivers - The revenue growth was primarily driven by overseas business and new product launches, despite a highly uncertain external environment and overall industry pressure [2] - The company effectively countered short-term pressures from centralized procurement and tariffs through localized marketing, accelerated new product launches, and cost reduction measures [2] Profit Margin Challenges - The decline in profit growth was mainly due to reduced gross margins from two key products, the hemostatic clip and microwave ablation needle, as a result of centralized procurement [2] - The company adopted a channel destocking strategy to cope with centralized procurement, which contributed to increased costs related to preliminary research and intermediary services for ongoing domestic and international investment projects [2] - Fluctuations in the RMB exchange rate also led to certain foreign exchange losses for the company [2] Executive Compensation - The chairman, Long Xiaohui, and the president, Leng Derong, both over 60 years old, have salaries of 4.87 million yuan and 4.896 million yuan respectively for 2024 [2]